View
Page
"Verona Pharma is at an exciting stage of its development with a new proprietary suspension formulation of its first-in-class RPL554. The proposed £44.7m equity capital raise announced Friday, supported by group of US and EU healthcare focused funds, enables the group to progress its development of RPL554 through to a Phase III ready stage. If development goes according to plan, RPL554 could be in a position to commence Phase III trials by the end of 2018." N+1 Singer's note out this morning on Research Tree
Latest from the Community...
Latest from the Community...
Latest from the Community...